CYP1A2

CYP1A2 (cytochrome P450 1A2) is a liver enzyme belonging to the cytochrome P450 superfamily — a family of proteins responsible for metabolizing most foreign compounds that enter the body. It handles a meaningful share of clinically used drugs and is the primary route of elimination for caffeine.

What distinguishes CYP1A2 from many other drug-metabolizing enzymes is how variable its activity is. Genetics play a role — some people carry variants that produce relatively fast or slow enzyme — but environmental factors matter just as much. Tobacco smoke contains polycyclic aromatic hydrocarbons that strongly induce the enzyme, sometimes doubling its activity. Quitting smoking, or starting certain medications, can shift that baseline substantially.

How it works · its role

CYP1A2 oxidizes its substrates — typically converting lipophilic compounds into more water-soluble forms the kidneys can excrete. For caffeine, this takes the form of N-demethylation, breaking the molecule down into paraxanthine and related metabolites.

Other compounds alter how well it functions. Inducers increase the enzyme's production, so substrates are cleared more quickly: plasma levels fall and effects or durations can shorten. Inhibitors block or compete with it, causing co-administered substrates to accumulate, raising their concentrations and extending their activity. Fluvoxamine, an SSRI used for OCD and anxiety, is among the most potent CYP1A2 inhibitors in common clinical use.

Genetic polymorphisms also contribute. Variant alleles can shift baseline activity up or down, meaning the same dose of a CYP1A2 substrate produces meaningfully different plasma concentrations across individuals — even before habits and co-medications enter the picture.

Relevance to substances & effects

Caffeine is the most familiar CYP1A2 substrate and is used in pharmacological research as a standard probe for measuring the enzyme's activity in vivo. Melatonin is another common substrate — potent inhibitors of CYP1A2 can substantially raise melatonin levels in people who take it as a supplement.

Several antipsychotics, including clozapine and olanzapine, rely heavily on CYP1A2 for clearance. This creates a recognised clinical hazard: a patient stabilised on one of these drugs at a dose calibrated to their smoking status may see plasma levels rise significantly when they quit, because the enzyme induction falls away. The reverse is also possible — beginning to smoke while on these drugs can push concentrations down, reducing efficacy.

Within the substances covered on these pages, CYP1A2 is most relevant to stimulants and other compounds that share this metabolic route, and to any combination that includes a potent inducer or inhibitor. Interaction severity is recorded in the interaction layer, where each finding carries its source; this entry describes the mechanism that underlies it.